BamSEC and AlphaSense Join Forces
Learn More

Biohaven Ltd. – Material Contracts

NYSE: BHVN    
Share price (5/22/26): $9.45    
Market cap (5/22/26): $1.422 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 7 pages Agreement for the Assignment of Notes
12/34/56
EX-10.2
from 10-Q 4 pages Material contract
12/34/56
EX-10.1
from 8-K 100 pages Note Purchase Agreement Dated as of April 28, 2025 Among Biohaven Therapeutics Ltd as Issuer, Biohaven Ltd. as Parent, the Other Obligors Party Hereto, the Purchasers Party Hereto, and Beetlejuice SA LLC as Purchaser Agent
12/34/56
EX-10.22
from 10-K 3 pages 1.66 “Selective Tyk2 Inhibitor” Means a Tyrosine Kinase (“Tky2”) Inhibitor With: (I) Ki <200nm Activity Inhibition in the Assay (For Both Allosteric and Non-Allosteric Tyk2 Inhibitors, (II) Brain Penetration Greater Than or Equal to Ten Percent (10%) and (III) 20x Times Greater Affinity to Tyk2 in a Cell Free Assay (Atp Dependent and Allosteric Assays) Over Jak1, Jak2 and Jak3, and Over 50x All Other Off-Targets (Including Kinome and Eurofins Secondary Pharmacology Panels)
12/34/56
EX-10.4
from 10-Q 17 pages Biohaven Ltd. Amendment to Share Option Grant Notice and Option Agreement
12/34/56
EX-10.3
from 10-Q 19 pages Biohaven Ltd. Nonstatutory Share Option Grant Notice
12/34/56
EX-10.2
from 10-Q 2 pages Material contract
12/34/56
EX-10.1
from 10-Q 47 pages Development and License Agreement Dual Tyk2/Jak1 Inhibitors
12/34/56
EX-10.18
from 10-K 10 pages Re: Amended and Restated Offer of Employment To: Bruce Car [***]
12/34/56
EX-10.18
from 10-Q 10 pages We Refer to the Offer of Employment Between You (“Employee”) and Biohaven Pharmaceuticals, Inc. (“Biohaven”). Dated August 1, 2022 (“Initial Agreement”). Following the Closing of the Merger of Biohaven Pharmaceutical Holding Company Ltd. With Pfizer Inc. on October 3, 2022, We Propose to Amend and Restate the Initial Agreement as Follows. the Following Terms and Conditions Will Govern This Employment (“Agreement”). Title: Chief Scientific Officer
12/34/56
EX-10.14
from 10-12B/A 2 pages Biohaven Ltd. Legacy Equity Award Settlement Plan Adopted by the Board of Directors: [●] Approved by the Shareholders: [●] Distribution Date: [●]
12/34/56
EX-10.17
from 10-12B/A 6 pages Biohaven Research Ltd. Employment Agreement
12/34/56
EX-10.16
from 10-12B/A 6 pages Biohaven Research Ltd. Employment Agreement
12/34/56
EX-10.15
from 10-12B/A 12 pages Biohaven Research Ltd. 2022 Employee Share Purchase Plan Adopted by the Board of Directors: [●] Approved by the Shareholders: [●]
12/34/56
EX-10.14
from 10-12B/A 2 pages Biohaven Research Ltd. Legacy Equity Award Settlement Plan Adopted by the Board of Directors: [●] Approved by the Shareholders: [●] Distribution Date: [●]
12/34/56
EX-10.13
from 10-12B/A 7 pages Biohaven Research Ltd. Share Option Grant Notice
12/34/56
EX-10.12
from 10-12B/A 8 pages Biohaven Research Ltd. Restricted Share Unit Grant Notice
12/34/56
EX-10.11
from 10-12B/A 27 pages Biohaven Research Ltd. 2022 Equity Incentive Plan Adopted by the Board of Directors: [●] Approved by the Shareholders: [●] Distribution Date: [●]
12/34/56
EX-10.10
from 10-12B 11 pages Employment Agreement
12/34/56
EX-10.9
from 10-12B 8 pages Employment Agreement
12/34/56